Scientific Board
LEAD CARDIOLOGY ADVISORS
Robert P. Giugliano, MD, SM
Brigham and Women’s Hospital, USA
Marc P. Bonaca, MD, MPH
Brigham and Women’s Hospital, USA
Jacob A. Udell, MD, MPH
Brigham and Women’s Hospital, USA
INTERNATIONAL MEDICAL ADVISORY BOARD
Edmund Chada Baracat, MD
Scientific Director,
Brazilian Medical Association
Jeroen J. Bax, MD, PhD
Leiden University Medical Center
The Netherlands
Richard M. Bergenstal, MD
President, Medicine & Science
American Diabetes Association
Ramon Corbalán, MD
Pontificia Universidad Católica, Chile
Jean-Pierre Després, PhD
Université Laval, Canada
Anthony N. DeMaria, MD
Editor-in-Chief, JACC
Vivian A. Fonseca, MD, FRCP
Tulane University, USA
Timothy J. Gardner, MD
Christiana Care Center for
Heart & Vascualr Health
Eva Gonçalvesova, MD, PhD
President, Slovak Society of Cardiology
Enrique Gurfinkel, MD, PhD
Fundación Favaloro, Argentina
Mariell Jessup, MD, FAHA
Scientific Sessions Program Chair
American Heart Association
David Kendall, MD
Chief Scientific and Medical Officer
American Diabetes Association
Milan Luknar, MD
National Institute of Cardiovascular
Disease, Slovak Republic
Raymond Massay, MD
President, Caribbean Cardiac Society
Anne L. Peters, MD, FACP, CDE
Univ. of Southern California, USA
Fausto Pinto, MD
CPC Chair, European Society of
Cardiology Congress 2009-2010
Christine T. Tobin, RN, MBA, CDE
President, Healthcare & Education
American Diabetes Association
 |
Official Peer-Reviewed Highlights from the |
ACC.11
60th Annual Scientific Session and i2 Summit 2011
Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?
Since its approval in 1997, clopidogrel has been a cornerstone of therapy in patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI) to reduce future ischemic events. Although the drug has led to significantly better outcomes, high variability in the antiplatelet effect has been demonstrated. A number of factors are responsible for this variability as demonstrated through pharmacodynamic and pharmacokinetic studies, including clinical factors and the presence of CYP2C19 loss-of-function alleles and reduced metabolism of clopidogrel to its active metabolite leading to attenuation of the intended anti-platelet effect [Brandt JT et al. J Thromb Haemost 2007]. See summary: Is It Time for Antiplatelet Therapy to Enter Personalized Medicine?